[go: up one dir, main page]

NO20090958L - Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid - Google Patents

Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid

Info

Publication number
NO20090958L
NO20090958L NO20090958A NO20090958A NO20090958L NO 20090958 L NO20090958 L NO 20090958L NO 20090958 A NO20090958 A NO 20090958A NO 20090958 A NO20090958 A NO 20090958A NO 20090958 L NO20090958 L NO 20090958L
Authority
NO
Norway
Prior art keywords
glucocorticoid
treatment
slow release
rheumatoid disease
rheumatoid
Prior art date
Application number
NO20090958A
Other languages
English (en)
Inventor
Achim Schaffler
Original Assignee
Nitec Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38739340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090958(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nitec Pharma Ag filed Critical Nitec Pharma Ag
Publication of NO20090958L publication Critical patent/NO20090958L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse refererer til behandling av en reumatismesykdom og/eller osteoartritt ved administrering av en doseringsform med langsom frigjøring av et glukokortikoid til et individ med behov derav.
NO20090958A 2006-08-03 2009-03-02 Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid NO20090958L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83509306P 2006-08-03 2006-08-03
PCT/EP2007/006894 WO2008015018A1 (en) 2006-08-03 2007-08-03 Delayed-release glucocorticoid treatment of rheumatoid disease

Publications (1)

Publication Number Publication Date
NO20090958L true NO20090958L (no) 2009-04-30

Family

ID=38739340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090958A NO20090958L (no) 2006-08-03 2009-03-02 Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid

Country Status (26)

Country Link
US (5) US20080076743A1 (no)
EP (1) EP2049123B2 (no)
JP (1) JP2009545546A (no)
KR (1) KR101430089B1 (no)
CN (1) CN101466385B (no)
AU (1) AU2007280636B2 (no)
BR (1) BRPI0717052A2 (no)
CA (1) CA2655682A1 (no)
DK (1) DK2049123T4 (no)
EA (1) EA015304B1 (no)
ES (1) ES2400446T5 (no)
HR (1) HRP20130148T4 (no)
IL (1) IL195155A (no)
MA (1) MA30665B1 (no)
MX (1) MX2009001248A (no)
MY (1) MY149863A (no)
NO (1) NO20090958L (no)
PL (1) PL2049123T5 (no)
PT (1) PT2049123E (no)
RS (1) RS52672B2 (no)
SG (2) SG174026A1 (no)
SI (2) SI2049123T1 (no)
TN (1) TNSN08385A1 (no)
UA (1) UA96457C2 (no)
WO (1) WO2008015018A1 (no)
ZA (1) ZA200809858B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
EP2391369A1 (en) 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
EP2563450B1 (en) * 2010-04-28 2017-07-26 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
CA2851322C (en) * 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) 1958-08-04 1962-08-07 Wander Company Medicinal tablet
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
BE629982A (no) 1962-04-06
FR1603314A (en) 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2100858B1 (no) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
DE2445971A1 (de) 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5519057A (en) 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE3930770A1 (de) 1989-09-14 1991-03-28 Wolfgang F Dr Schoener Implantierbare katheter aus medizinisch vertraeglichem elastischen kunststoff
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
DK0537139T3 (da) 1990-07-02 1994-08-22 Boehringer Mannheim Gmbh Fremgangsmåde til fremstilling af formede, pressede dosisenheder med forsinket frigørelse og dertil svarende dosisenhed
JP2521848B2 (ja) 1990-07-02 1996-08-07 ベーリンガー マンハイム ゲーエムベーハー 成形され、圧縮された徐放性単位投薬形態の調製法およびこうして得られた圧縮単位投薬形態
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5310578A (en) 1990-09-17 1994-05-10 Merck Patent Gesellschaft Deposition of cosmetically functional material onto pigments and fillers
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
WO1992011845A1 (en) 1991-01-03 1992-07-23 Glaxo Canada Inc. Method for production of solid pharmaceutical preparation
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
EP0546593B1 (en) 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
AU3949093A (en) 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
GB9215908D0 (en) 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
CA2142982A1 (en) 1992-09-30 1994-04-14 Julian Belknap Lo Articles for sustained release of medications
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
TW272942B (no) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5709880A (en) 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU1751997A (en) 1996-01-30 1997-08-22 Advanced Polymer Systems Inc. Targeted delivery of drugs to the lower gastrointestinal tract
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US6190591B1 (en) 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
EP0999830A1 (en) 1997-07-01 2000-05-17 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
NZ503820A (en) 1997-10-09 2004-02-27 Dexcel Pharma Technologies Ltd A delayed followed by immediate release drug delivery system containing a core and a coating
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
DE60042352D1 (de) 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
ES2436523T3 (es) 2001-03-13 2014-01-02 Endo Pharmaceuticals Inc. Formas de dosificación terapéutica
CA2441007C (en) 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
IN191028B (no) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
US7776345B2 (en) 2001-07-04 2010-08-17 Sun Pharma Advanced Research Company Ltd Gastric retention controlled drug delivery system
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CN1592610A (zh) 2001-09-28 2005-03-09 麦克内尔-Ppc股份有限公司 改良的释放剂型
CA2463495C (en) 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US20080145438A1 (en) 2001-12-20 2008-06-19 Beuford Arlie Bogue Micro- and nano-particulate drugs and methods of making thereof
WO2003061626A1 (en) 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
AU2003208761A1 (en) 2002-02-21 2003-09-09 Amarin Development Ab A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
WO2003075919A1 (fr) 2002-03-14 2003-09-18 Daiichi Suntory Pharma Co.,Ltd. Comprime contenant du chlorhydrate de pilsicainide (voie seche)
AU2003230691A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
RU2005108577A (ru) 2002-09-28 2006-06-10 МакНЕЙЛ-ППС, ИНК. (US) Дозированные формы с модифицированным высвобождением
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2504610C (en) 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
PL1631251T3 (pl) 2003-04-24 2011-12-30 Jagotec Ag Tabletka o opóźnionym uwalnianiu i o określonej geometrii
EP1615626B1 (en) 2003-04-24 2009-10-14 Jagotec Ag Tablet with coloured core
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
AU2004273958A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
JP5134955B2 (ja) * 2004-09-10 2013-01-30 ヤゴテック アクチエンゲゼルシャフト 活性成分の部位時間制御胃腸放出作用を有する錠剤
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0427455D0 (en) 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US20090110633A1 (en) 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
AU2006261788B2 (en) 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
UA91376C2 (ru) 2005-08-24 2010-07-26 Рубикон Рисеч Пвт Лтд. Рецептура с контролируемым высвобождением
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2631757A1 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
EP2049084A2 (en) 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
US20080014272A1 (en) 2006-07-11 2008-01-17 Phil Skolnick Compositions and Methods for Treatment of Chronic Pain Conditions
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
AU2007281433A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2063872B2 (en) 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
EA200970260A1 (ru) 2006-09-08 2009-08-28 Фоамикс Лтд. Окрашенная или окрашиваемая и вспениваемая композиция и пена
WO2008033351A2 (en) 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations
US20080113002A1 (en) 2006-11-14 2008-05-15 Saul Yedgar Contact lens compositions
WO2008079963A2 (en) 2006-12-22 2008-07-03 Cambrex Charles City, Inc. Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
WO2008094877A2 (en) 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US20100016322A1 (en) 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
BRPI0809282B8 (pt) 2007-04-13 2021-05-25 Dow Global Technologies Inc material granular, material de partida para uma forma de dosagem, forma de dosagem, processo de compressão direta para preparar uma forma de dosagem, uso do material granular e processo para granular um pó de polímero
CA2684219C (en) 2007-04-13 2017-05-23 Chemgenex Pharmaceuticals, Inc. Oral cephalotaxine dosage forms
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US9642808B2 (en) 2007-08-13 2017-05-09 Panacea Biotech Limited Extended release compositions comprising mycophenolate sodium and processes thereof
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
WO2009042778A1 (en) 2007-09-25 2009-04-02 Nirmal Mulye Controlled release pharmaceutical compositions
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
JP2011500553A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20130184220A1 (en) 2007-12-21 2013-07-18 Bradford James Duft Treatment of abnormal or excessive scars
JP2011507861A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
US20110243964A1 (en) 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
CA2717456A1 (en) 2008-03-05 2009-09-11 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2009152479A1 (en) 2008-06-12 2009-12-17 University Of Alabama Huntsville Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases of trauma
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2391369A1 (en) 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage

Also Published As

Publication number Publication date
KR20090045149A (ko) 2009-05-07
CA2655682A1 (en) 2008-02-07
CN101466385A (zh) 2009-06-24
SI2049123T1 (sl) 2013-04-30
PT2049123E (pt) 2013-03-06
HRP20130148T1 (en) 2013-03-31
CN101466385B (zh) 2014-01-08
US8920838B2 (en) 2014-12-30
MY149863A (en) 2013-10-31
WO2008015018A1 (en) 2008-02-07
US20120070499A1 (en) 2012-03-22
HK1130423A1 (en) 2009-12-31
ES2400446T5 (es) 2017-03-13
US20080076743A1 (en) 2008-03-27
HRP20130148T4 (hr) 2016-10-07
EA015304B1 (ru) 2011-06-30
SI2049123T2 (sl) 2016-10-28
DK2049123T4 (en) 2016-11-28
AU2007280636A1 (en) 2008-02-07
RS52672B2 (sr) 2018-03-30
UA96457C2 (ru) 2011-11-10
ES2400446T3 (es) 2013-04-09
IL195155A0 (en) 2009-09-22
EA200900259A1 (ru) 2009-06-30
RS52672B (sr) 2013-06-28
BRPI0717052A2 (pt) 2013-10-15
EP2049123A1 (en) 2009-04-22
US20140065214A1 (en) 2014-03-06
MX2009001248A (es) 2009-02-11
ZA200809858B (en) 2009-10-28
AU2007280636B2 (en) 2013-07-18
SG10201503411QA (en) 2015-06-29
EP2049123B2 (en) 2016-08-24
US20170281648A1 (en) 2017-10-05
KR101430089B1 (ko) 2014-08-13
SG174026A1 (en) 2011-09-29
US9504699B2 (en) 2016-11-29
MA30665B1 (fr) 2009-08-03
PL2049123T3 (pl) 2013-04-30
TNSN08385A1 (en) 2009-12-29
US20150141388A1 (en) 2015-05-21
DK2049123T3 (da) 2013-03-04
IL195155A (en) 2016-05-31
EP2049123B1 (en) 2012-11-28
JP2009545546A (ja) 2009-12-24
PL2049123T5 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
NO20090958L (no) Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
DK2170360T3 (da) Urtesammensætning til behandling af diabetes og/eller forstyrrelser forbundet dermed
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
UA109658C2 (xx) Антитіло проти cgrp
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009011500A (es) Anticuerpos anti-mdl-1.
EP1848432A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES COMPRISING OBESITY, DIABETES, METABOLIC SYNDROMES, NEURODEGENERATIVE DISEASES, AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
MX2009011316A (es) Derivados del acido lipoico.
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
DK2172207T3 (da) Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application